FKBP-12
15 drugs OncologyImmunology
7
approved indications
15
Approved Drugs
11
Companies
12
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (11 companies)
✓ All 15 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (12 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Novartis 3 drugs
PF PRISM CV 2 drugs
ASTELLAS 2 drugs
By Therapeutic Area
Other 9 drugs
Oncology 4 drugs
Drugs by Company PRO
Novartis 3 drugs
ASTELLAS 2 drugs
ALKEM LABS LTD 1 drug
AADI SUB 1 drug
GLAND 1 drug
VELOXIS PHARMS INC 1 drug
Teva 1 drug
BAUSCH 1 drug
LEO PHARMA AS 1 drug
+ 1 more companies
By Therapeutic Area
Other 9 drugs
SIROLIMUS, RAPAMUNE, ASTAGRAF XL, PROGRAF +5 more
Oncology 4 drugs
AFINITOR, AFINITOR DISPERZ, TEMSIROLIMUS, TORISEL
Immunology 2 drugs
PIMECROLIMUS, ELIDEL
Indications Treated
Organ RejectionMalignant Perivascular Epithelioid Cell TumorLymphangioleiomyomatosisRenal Cell CarcinomaBreast CancerNeuroendocrine TumorsRenal AngiomyolipomaTuberous Sclerosis ComplexSubependymal Giant Cell AstrocytomaSeizuresAtopic DermatitisPartial-Onset Seizures
All Drugs Targeting FKBP-12
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| AFINITOR Top | Novartis | 2009 | 7 | Oncology |
| AFINITOR DISPERZ Top | Novartis | 2012 | 7 | Oncology |
| SIROLIMUS | ALKEM LABS LTD | 2014 | 2 | |
| RAPAMUNE | PF PRISM CV | 1999 | 2 | |
| ASTAGRAF XL | ASTELLAS | 2013 | 1 | |
| PROGRAF | ASTELLAS | 1994 | 1 | |
| FYARRO | AADI SUB | 2021 | 1 | |
| TEMSIROLIMUS | GLAND | 2018 | 1 | Oncology |
| ENVARSUS XR | VELOXIS PHARMS INC | 2015 | 1 | |
| PIMECROLIMUS | Teva | 2018 | 1 | Immunology |
| ELIDEL | BAUSCH | 2001 | 1 | Immunology |
| ZORTRESS | Novartis | 2010 | 1 | |
| TORISEL | PF PRISM CV | 2007 | 1 | Oncology |
| PROTOPIC | LEO PHARMA AS | 2000 | 1 | |
| TACROLIMUS | ACCORD HLTHCARE | 2009 | - |